IL92495A - Medicinal product containing recombinant human alpha interphone for the treatment of LLEC SUOMAUQS carcinoma in dose into the tumor - Google Patents
Medicinal product containing recombinant human alpha interphone for the treatment of LLEC SUOMAUQS carcinoma in dose into the tumorInfo
- Publication number
- IL92495A IL92495A IL9249589A IL9249589A IL92495A IL 92495 A IL92495 A IL 92495A IL 9249589 A IL9249589 A IL 9249589A IL 9249589 A IL9249589 A IL 9249589A IL 92495 A IL92495 A IL 92495A
- Authority
- IL
- Israel
- Prior art keywords
- interferon
- squamous cell
- cell carcinoma
- treatment
- intralesionally
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27831588A | 1988-12-01 | 1988-12-01 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL92495A0 IL92495A0 (en) | 1990-08-31 |
| IL92495A true IL92495A (en) | 1995-05-26 |
Family
ID=23064525
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL9249589A IL92495A (en) | 1988-12-01 | 1989-11-29 | Medicinal product containing recombinant human alpha interphone for the treatment of LLEC SUOMAUQS carcinoma in dose into the tumor |
Country Status (14)
| Country | Link |
|---|---|
| EP (2) | EP0372809B1 (da) |
| JP (1) | JPH0647556B2 (da) |
| KR (1) | KR950011889B1 (da) |
| AT (1) | ATE92333T1 (da) |
| AU (1) | AU634511B2 (da) |
| CA (1) | CA2004202C (da) |
| DE (1) | DE68908119T2 (da) |
| DK (1) | DK103891A (da) |
| ES (1) | ES2058555T3 (da) |
| IE (1) | IE63121B1 (da) |
| IL (1) | IL92495A (da) |
| MY (1) | MY107071A (da) |
| WO (1) | WO1990006135A1 (da) |
| ZA (1) | ZA899113B (da) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2098393A1 (en) * | 1990-12-14 | 1992-06-15 | Robert J. Spiegel | Oral administration of alpha interferon to treat lung malignancies |
| PT99837A (pt) * | 1990-12-21 | 1992-12-31 | Schering Corp | Processo para a preparacao de composicoes farmaceuticas contendo interferao alfa e metodo para administracao de interferao alfa por inalacao oral para tratar asma e doencas pulmonares proliferativas nao malignas |
| JP4156028B2 (ja) * | 1995-10-04 | 2008-09-24 | シェーリング コーポレイション | 進行癌の処置のためのテモゾロミドとα−ＩＦＮの組合せ |
| US7294332B2 (en) | 1995-10-04 | 2007-11-13 | Schering Corporation | Combination therapy (temozolomide and α-IFN) for advanced cancer |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0077063B1 (en) * | 1981-10-13 | 1988-03-16 | Exovir, Inc. | Interferon-containing compositions and the use of these compositions in the treatment of herpetic infections, pre-malignant skin lesions, skin malignancies and psoriasis |
| ZA873743B (en) * | 1986-05-27 | 1987-11-25 | Schering Corporation | Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon |
-
1989
- 1989-11-29 AU AU48025/90A patent/AU634511B2/en not_active Ceased
- 1989-11-29 WO PCT/US1989/005287 patent/WO1990006135A1/en not_active Application Discontinuation
- 1989-11-29 ES ES89312404T patent/ES2058555T3/es not_active Expired - Lifetime
- 1989-11-29 CA CA002004202A patent/CA2004202C/en not_active Expired - Fee Related
- 1989-11-29 EP EP89312404A patent/EP0372809B1/en not_active Expired - Lifetime
- 1989-11-29 EP EP90900655A patent/EP0446279A1/en active Pending
- 1989-11-29 JP JP2501299A patent/JPH0647556B2/ja not_active Expired - Lifetime
- 1989-11-29 ZA ZA899113A patent/ZA899113B/xx unknown
- 1989-11-29 KR KR1019900701665A patent/KR950011889B1/ko not_active IP Right Cessation
- 1989-11-29 DE DE89312404T patent/DE68908119T2/de not_active Expired - Fee Related
- 1989-11-29 IL IL9249589A patent/IL92495A/en not_active IP Right Cessation
- 1989-11-29 MY MYPI89001661A patent/MY107071A/en unknown
- 1989-11-29 AT AT89312404T patent/ATE92333T1/de not_active IP Right Cessation
- 1989-11-30 IE IE382889A patent/IE63121B1/en not_active IP Right Cessation
-
1991
- 1991-05-31 DK DK103891A patent/DK103891A/da not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO1990006135A1 (en) | 1990-06-14 |
| KR900701311A (ko) | 1990-12-01 |
| IE893828L (en) | 1990-06-01 |
| DK103891D0 (da) | 1991-05-31 |
| MY107071A (en) | 1995-09-30 |
| JPH0647556B2 (ja) | 1994-06-22 |
| KR950011889B1 (ko) | 1995-10-12 |
| EP0372809B1 (en) | 1993-08-04 |
| ES2058555T3 (es) | 1994-11-01 |
| JPH04500678A (ja) | 1992-02-06 |
| CA2004202A1 (en) | 1990-06-01 |
| IL92495A0 (en) | 1990-08-31 |
| DE68908119D1 (de) | 1993-09-09 |
| AU4802590A (en) | 1990-06-26 |
| AU634511B2 (en) | 1993-02-25 |
| ZA899113B (en) | 1990-08-29 |
| CA2004202C (en) | 2001-02-13 |
| IE63121B1 (en) | 1995-03-22 |
| DE68908119T2 (de) | 1993-11-18 |
| ATE92333T1 (de) | 1993-08-15 |
| EP0372809A1 (en) | 1990-06-13 |
| EP0446279A1 (en) | 1991-09-18 |
| DK103891A (da) | 1991-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wickramasinghe et al. | Treatment of neoplastic skin lesions with intralesional interferon | |
| US5028422A (en) | Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon | |
| US5256410A (en) | Treatment of squamous cell carcinoma intralesionally with recombinant human alpha interferon | |
| IE64765B1 (en) | Use of cytokines | |
| Edwards et al. | Effect of intralesional a2-interferon on actinic keratoses | |
| US5480640A (en) | Alpha interferon for treating prostate cancer | |
| Bernard et al. | Transient focal neurologic deficits complicating interleukin‐2 therapy | |
| US5002764A (en) | Treatment of actinic keratoses with alpha2 interferon | |
| EP0225759B1 (en) | Interferon compositions | |
| AU634511B2 (en) | Treatment of squamous cell carcinoma intralesionally with recombinant human alpha interferon | |
| Doǧan et al. | Intralesional alfa-2a interferon therapy for basal cell carcinoma | |
| EP0248583B1 (en) | Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon | |
| Bleeker | Intralesional triamcinolone acetonide using the Port‐O‐Jet and needle injections in localized dermatoses | |
| Bartkowski-Dodds et al. | Use of sodium bicarbonate as a means of ameliorating doxorubicin-induced dermal necrosis in rats | |
| Ikić et al. | Interferon reduces recurrences of basal cell and squamous cell cancers | |
| EP0369632A1 (en) | Treatment of genital warts with a combination of liquid nitrogen and recombinant DNA human alpha interferon | |
| Hussein | Interleukin 1 protects against 1-β-D-arabinofuranosylcytosine-induced alopecia in the newborn rat animal model | |
| Brody | Electrical Activity in Sympathetic Nerves of Immunologically Sympathectomized Rats. | |
| DE69028020T2 (de) | Antitumorzusammensetzung die polypeptide mit der aktivität des humanen interleukin-2 enthält | |
| Shuttleworth et al. | A comparison of the effects of intralesional interferon α-2b and topical 5% 5-fluorouracil cream in the treatment of solar keratoses and Bowen's disease | |
| Lee et al. | Clinical trials of interferon-gamma in treating warts | |
| Cho et al. | Basal Cell Carcinoma and Actinic Keratosis Treated with Intralesional Injection of Recombinant Alpha-2 Interferon | |
| von Wussow | INTRALESIONAL INTERFERON-ALPHA-THERAPY IN ADVANCED MALIGNANT MELANOMA Peter von Wussow Dept. of Clinical Immunology, Medical School of Hannover, Hannover, West-Germany | |
| Cho et al. | Intralesional Injection of Recombinant Alpha-2 Interferon | |
| Fushiki et al. | Effects of granulocyte colony-stimulating factor on the radio-sensitivity of CFU-S in mice |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RH | Patent void |